Pharmaceuticals 2010, 3(11), 3478-3493; doi:10.3390/ph3113478
Review

Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease

 and * email
Received: 21 September 2010; in revised form: 27 October 2010 / Accepted: 8 November 2010 / Published: 9 November 2010
(This article belongs to the Special Issue GPCR Based Drug Discovery)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Patients with hypertension often manifest a dysregulated renin-angiotensin-aldosterone system (RAAS). Most of the available treatment approaches for hypertension are targeted towards the RAAS including direct renin inhibition, ACE inhibition, angiotensin II type 1 receptor (AT1-R) blockade, and aldosterone receptor antagonism. The Jak2 signaling pathway is intricately coupled to the AT1-R signaling processes involved in hypertension. Here, we review the involvement of Jak2 in the pathogenesis of hypertension, and its potential as a therapeutic target for treatment of AT1-R mediated cardiovascular disease. Jak2 may provide a rational therapeutic approach for patients whose blood pressure is not controlled by standard therapies.
Keywords: angiotensin II; Jak2; AT1-receptor; hypertension
PDF Full-text Download PDF Full-Text [307 KB, uploaded 9 November 2010 12:35 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Kirabo, A.; Sayeski, P.P. Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. Pharmaceuticals 2010, 3, 3478-3493.

AMA Style

Kirabo A, Sayeski PP. Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. Pharmaceuticals. 2010; 3(11):3478-3493.

Chicago/Turabian Style

Kirabo, Annet; Sayeski, Peter P. 2010. "Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease." Pharmaceuticals 3, no. 11: 3478-3493.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert